I hear you Van on your fairly valued argument and I agree these guys kicked ass. But they have flat lined here post Covid and the company is doing enough internally. They are going to be buying back shares I am pretty sure. The HF likes a premise and I can sell this. We have one troublesom section of the co which is widely known-- The anticipated weakness in its Viessmann business, <-----which accounts for roughly a mid-teens percentage of the company's FY24E revenue. ->the negative impact of Viessmann could be substantially mitigated by synergies from the Viessmann partnership and broader productivity initiatives. Carrier Global's core markets are likely to experience mid-single-digit growth in the coming years. This projection is based on the bottoming out of the U.S. residential and global transport sectors,<--- There has been a slow down and now we can speed up coupled with persistent strength in the commercial HVAC market. Carrier Global's journey towards improvement may not be linear but the company's efficient management and dominant market share in a preferred end market indicate potential for further growth.
Anybody else like Solid Bio? I've had this on watch for a few weeks. I think we should move on it. Insider buying
I have a disease called CMT. Nobody's heard of it. I think I look pretty good but my hair it's not good up there. I've just turned sixty. That was my birthday trip to Nevis.
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 — — FDA cleared IND and granted Fast Track Designation and Orphan Drug Designation for Duchenne muscular dystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trial expected Q2 2024 — — Company entered into non-exclusive licensing agreement for use of its proprietary, muscle-targeted AAV-SLB101 capsid — CHARLESTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. "2023 was an exciting and transformational year for Solid where we completed the integration with AavantiBio, while diversifying and expanding our pipeline. We strengthened our management team with the hiring of a CMO, Dr. Gabriel Brooks, and CFO, Kevin Tan, and advanced our next generation gene therapy for Duchenne, SGT-003, towards the clinic with IND clearance in Q4 and received Fast Track Designation and Orphan Drug Designation in Q4 2023 and Q1 2024, respectively. We continued to bring in additional assets, including SGT-501 for the treatment of a fatal childhood disease called CPVT from ICS Maugeri, while moving additional high potential programs and capsids through preclinical models,” said Bo Cumbo, President and CEO of Solid Biosciences. “We enter 2024 with significant momentum from our recently completed financing in January which raised $108.9 million from a syndicate of leading investors. 2024 will be a year of execution and we look forward to rapidly bringing SGT-003 into the clinic, advancing SGT-501 towards IND filing and most importantly, continuing to bring hope to all those suffering from devastating genetic diseases.” Company Updates Solid expects to initiate dosing in the Phase 1/2 trial of SGT-003 in pediatric patients with Duchenne in the second quarter of 2024. A safety update is expected mid-year and initial data from the first two cohorts of the trial is expected in Q4 2024. Solid announced it expects to file an IND for its first cardiac gene therapy candidate, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), in the first quarter of 2025. Solid has entered into a non-exclusive licensing agreement for use of its proprietary, muscle-targeted AAV-SLB101 capsid. Solid aims to license AAV-SLB101 broadly to both companies and academic institutions pursuing treatments for rare diseases.